Treatment of Hepatitis B in HIV-Infected Persons

  • Ellen Kitchell
  • Mamta K. Jain


Hepatitis B virus (HBV) is a potentially controllable infection, but it is rarely eliminated from the body. During HBV replication, a covalently closed circular DNA molecule is formed, which remains intracellular and serves as a persistent reservoir that can cause reactivation of HBV infection years after a patient discontinues therapy.


HBeAg Seroconversion Adefovir Dipivoxil Lamivudine Monotherapy Monoinfected Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.PubMedCrossRefGoogle Scholar
  3. 3.
    Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive team on anti-viral treatment. J Viral Hepat. 1998;5(6):389–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507–39.PubMedCrossRefGoogle Scholar
  5. 5.
    Brook MG, Chan G, Yap I, et al. Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ. 1989;299(6700):652–6.PubMedCrossRefGoogle Scholar
  6. 6.
    McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology. 1987;7(4):719–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis. 2003;37(12):1678–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119(4):312–23.PubMedGoogle Scholar
  9. 9.
    Di Martino V, Thevenot T, Boyer N, Degos F, Marcellin P. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology. 2000;31(4):1030–1.PubMedGoogle Scholar
  10. 10.
    Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10(4):298–305.PubMedCrossRefGoogle Scholar
  11. 11.
    Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999;180(3):607–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 1996;125(9):705–12.PubMedGoogle Scholar
  13. 13.
    Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis. 2001;32(6):963–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Haverkamp M, Smit M, Weersink A, Boucher CA, Hoepelman AI. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count). AIDS. 2003;17(10):1572–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30(5):1302–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20(6):863–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999;28(5):1032–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. AIDS. 2000;14(9):1111–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Yuen MF, Chow DH, Tsui K, et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005;21(7):841–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Jang JW, Choi JY, Bae SH, et al. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients. J Med Virol. 2005;77(3):367–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim YJ, Kim BG, Jung JO, Yoon JH, Lee HS. High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol. 2006;41(3):240–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Raffi F, Snow A, Borroto-Esoda K, et al. Anti-HBV activity of emtricitabine (FTC) in patients co-infected with HIV and hepatitis B virus. [Oral presentation]. Paper presented at: 2nd International AIDS Conference on Pathogenesis and Treatment; July 13–16, 2003. Paris, France; 2003.Google Scholar
  23. 23.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Kim do Y, Kim HJ, Lee CK, et al. Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. Liver Int. 2007;27(1):47–53.PubMedGoogle Scholar
  26. 26.
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808–16.PubMedCrossRefGoogle Scholar
  27. 27.
    Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44(1):108–16.PubMedCrossRefGoogle Scholar
  28. 28.
    Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126(1):91–101.PubMedCrossRefGoogle Scholar
  29. 29.
    Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol. 2006;44(1 Suppl):S90–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and ­lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001;358(9283):718–23.PubMedCrossRefGoogle Scholar
  31. 31.
    Delaugerre C, Marcelin AG, Thibault V, et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother. 2002;46(5):1586–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10(6):727–34.PubMedGoogle Scholar
  33. 33.
    Karatayli E, Karayalcin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007;12(5):761–8.PubMedGoogle Scholar
  34. 34.
    Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354(17):1807–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125(2):292–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Benhamou Y, Piketty C, Katlama C, et al. Anti-hepatitis B virus (HBV) activity of tenofovir dispoproxil fumarate (TDF) in human immunodeficiency virus (HIV) co-infected patients [abstract]. Hepatology. 2003;38(4):712A–3.CrossRefGoogle Scholar
  37. 37.
    Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189(7):1185–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS. 2003;17(1):F7–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis. 2002;186(12):1844–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-­containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother. 2005;56(6):1087–93.PubMedCrossRefGoogle Scholar
  41. 41.
    van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40(6):1421–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44(5):1110–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–55.PubMedCrossRefGoogle Scholar
  44. 44.
    Audsley J, Arrifin N, Yuen LK, et al. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. HIV Med. 2009;10(4):229–35.PubMedCrossRefGoogle Scholar
  45. 45.
    Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12(3):355–62.PubMedGoogle Scholar
  46. 46.
    van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44(2):318–25.PubMedCrossRefGoogle Scholar
  47. 47.
    Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22(16):2155–63.PubMedCrossRefGoogle Scholar
  48. 48.
    Chang TT, Lai CL. Hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;355(3):322–3. author reply 323.PubMedCrossRefGoogle Scholar
  49. 49.
    Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–20.PubMedCrossRefGoogle Scholar
  50. 50.
    Pessoa MG, Gazzard B, Huang AK, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS. 2008;22(14):1779–87.PubMedCrossRefGoogle Scholar
  51. 51.
    Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48(9):3498–507.PubMedCrossRefGoogle Scholar
  52. 52.
    Jain MK, Zoellner CL. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naive patient treated for chronic HBV. AIDS. 2007;21(17):2365–6.PubMedCrossRefGoogle Scholar
  53. 53.
    McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir – effects on HIV-1 replication and resistance. N Engl J Med. 2007;356(25):2614–21.PubMedCrossRefGoogle Scholar
  54. 54.
    Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS. 2008;22(8):947–55.PubMedCrossRefGoogle Scholar
  55. 55.
    Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486–95.PubMedCrossRefGoogle Scholar
  56. 56.
    Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147(11):745–54.PubMedGoogle Scholar
  57. 57.
    Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS. 2009;23(4):546–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Milazzo L, Caramma I, Lai A, et al. Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir Ther. 2009;14(6):869–72.PubMedCrossRefGoogle Scholar
  59. 59.
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576–88.PubMedCrossRefGoogle Scholar
  60. 60.
    Kaymakoglu S, Oguz D, Gur G, et al. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007;51(8):3020–2.PubMedCrossRefGoogle Scholar
  61. 61.
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95.PubMedCrossRefGoogle Scholar
  62. 62.
    Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005;100(11):2463–71.PubMedCrossRefGoogle Scholar
  63. 63.
    Shi M, Wang RS, Zhang H, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother. 2006;58(5):1031–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008;48(5):714–20.PubMedCrossRefGoogle Scholar
  65. 65.
    Wang LC, Chen EQ, Cao J, et al. Combination of lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. J Viral Hepat. 2010;17(3):178–84.PubMedCrossRefGoogle Scholar
  66. 66.
    Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008;48(5):728–35.PubMedCrossRefGoogle Scholar
  67. 67.
    Jain MK, Comanor L, White C, et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat. 2007;14(3):176–82.PubMedCrossRefGoogle Scholar
  68. 68.
    Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis. 2004;39(7):1062–4.PubMedCrossRefGoogle Scholar
  69. 69.
    Nelson M, Bhagani S, Fisher M, et al. A 48-week study of tenofovir or lamivudine or a combination of tenofovir and lamivudine for the treatment of chronic hepatitis B in HIV/HBV co-infected individuals. Paper presented at: Conference on Retroviruses and Opportunisitic Infections; February 5–8, 2006. Denver, Colorado; 2006.Google Scholar
  70. 70.
    Matthews GV, Seaberg E, Dore GJ, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009;23(13):1707–15.PubMedCrossRefGoogle Scholar
  71. 71.
    Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology. 2008;48(4):1062–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008. Accessed 1 June 2010.Google Scholar
  73. 73.
    Jain MK, Opio CK, Osuagwu CC, Pillai R, Keiser P, Lee WM. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy? Clin Infect Dis. 2007;44(7):996–1000.PubMedCrossRefGoogle Scholar
  74. 74.
    Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006;43(3):548–55.PubMedCrossRefGoogle Scholar
  75. 75.
    Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44(9):991–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355–65.PubMedCrossRefGoogle Scholar
  77. 77.
    Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42(5):615–24.PubMedCrossRefGoogle Scholar
  78. 78.
    Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9(2):82–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207. quiz CE201–204.Google Scholar
  80. 80.
    Brook G, Main J, Nelson M, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med. 2010;11(1):1–30.PubMedCrossRefGoogle Scholar
  81. 81.
    Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008;22(12):1399–410.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Internal Medicine, Southwestern Medical CenterUniversity of TexasDallasUSA
  2. 2.Department of Internal MedicineUT Southwestern Medical CenterDallasUSA

Personalised recommendations